![]() G1 Therapeutics G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. | Zyngenia Zyngenia is a company developing biotherapeutics that simultaneously target multiple physiologic pathways. | |||
Founding Date | Founding Date 2008 | Founding Date 2009 | Founding Date 1992 | Founding Date 2009 |
Type | Type Public | Type Private | Type Public | Type Subsidiary |
Tags | ||||
Locations | Locations Durham, US HQ | Locations Washington, US HQ | Locations Somerville, US HQ | Locations Santa Monica, US HQ Hoofddorp, NL London, GB El Segundo, US Emeryville, US Frederick, US Oceanside, US see more |
Employees | Employees 17015% increase | Employees N/A | Employees 32338% decrease | Employees 4,008 |
Valuation ($) | Valuation ($) 377.2 m | Valuation ($) N/A | Valuation ($) 95.4 m | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) $82.5m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $83.8m (FY, 2024) | Revenue (est.) N/A |
Net income | Net income ($48m) (FY, 2023) | Net income N/A | Net income ($240.7m) (FY, 2024) | Net income N/A |
Operating ⚠ | ||||
Patents and Patent Applications | Patents and Patent Applications 350 (FY, 2020) | Patents and Patent Applications N/A | Patents and Patent Applications 1.2 k (FY, 2020) | Patents and Patent Applications N/A |
Funding | ||||
Total funding raised | Total funding raised $ 289.6m | Total funding raised $ 25m | Total funding raised $ 409m | Total funding raised $ 85.3m |
Zyngenia is a company developing biotherapeutics that simultaneously target multiple physiologic pathways.
View companyBluebird Bio is a developer of gene therapies for severe genetic diseases.
View companyKite Pharma is a company developing cancer immunotherapy products based on cell therapy.
View company